BioSpace News Archive

Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related kinase 7 -directed MGD.

Webcast to be held Monday, March 18th, 4:30 p.m. ET, register for the webcast here , or at the link provided below.

Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”), (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the first Phase 1b/2a clinical trial of SON-080 was cleared to proceed to Phase 2 after review by the independent DSMB.

Qu Biologics Inc. is pleased to announce, in partnership with TransBIOTech (Quebec), being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that the U.S. Food and Drug Administration has lifted the partial clinical hold on the U.S. Phase 1a/1b study evaluating NX-2127 in adults with relapsed/refractory B-cell malignancies.

ADMA Biologics, Inc. announced the United States Food and Drug Administration’s approval for its supplemental Biologics License Applications for both ASCENIV and BIVIGAM to extend the approved 4-week room temperature storage conditions during the first 24 months of shelf life, to allow for a 4-week room temperature storage at any time during the entire 36-month approved shelf life.

Apellis Pharmaceuticals, Inc. announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18.

Progyny, Inc. today announced that Pete Anevski, Progyny’s Chief Executive Officer, and Michael Sturmer, Progyny’s President, will participate in a fireside chat at Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024 at 10:15 A.M. Eastern Time.

An artificial intelligence tool can convert doctor-written notes that summarize patients’ hospital visits into accurate, lay language, a new study found.